下一代肿瘤不可知靶点即将出现
Next-generation tumor-agnostic targets on the horizon.
肿瘤不可知药物开发将肿瘤学重新聚焦于共享的分子依赖性而非组织来源,从而能够针对跨肿瘤的罕见可操作驱动因素进行高效开发。
英文原题:AZIN1-dependent polyamine synthesis accelerates tumor cell cycle progression and impairs effector T-cell function in osteosarcoma.
我们的研究结果确立了AZIN1-多胺轴在骨肉瘤增殖和免疫逃逸中的关键作用,并支持开发靶向多胺生物合成的新型免疫治疗策略以对抗这种侵袭性癌症。
骨肉瘤是青少年中最常见的恶性骨肿瘤,常对免疫治疗表现出有限应答,这一难题归因于对其潜在机制了解不足。在此,我们将多胺生物合成的增强确定为骨肉瘤进展和免疫治疗耐药的关键驱动因素。我们表明,骨肉瘤细胞增殖和肿瘤生长依赖于多胺的可利用性,而破坏多胺合成可显著增强TCR工程化T细胞对骨肉瘤细胞的细胞毒性效力。在机制上,我们揭示,敲低抗酶抑制剂1(AZIN1)或抑制多胺生成可降低MYC表达,通过下调细胞周期相关基因导致肿瘤细胞活力下降。此外,MYC水平降低与免疫调节细胞因子和人类白细胞抗原分子表达的变化相关,提示其可能与增强T细胞介导的细胞毒性存在联系。总体而言,我们的发现确立了AZIN1-多胺轴在骨肉瘤增殖和免疫逃逸中的关键作用,并支持开发靶向多胺生物合成的新型免疫治疗策略以对抗这种侵袭性癌症。
Osteosarcoma, the most prevalent malignant bone tumor among adolescents, frequently exhibits limited responsiveness to immunotherapy, a challenge attributed to poorly understood underlying mechanisms. Here, we identify enhanced polyamine biosynthesis as a key driver of osteosarcoma progression and immunotherapy resistance. We show that osteosarcoma cell proliferation and tumor growth rely on polyamine availability and that disruption of polyamine synthesis significantly boosts the cytotoxic efficacy of TCR-engineered T cells against osteosarcoma cells. Mechanistically, we reveal that the knockdown of antizyme inhibitor 1 (AZIN1) or suppression of polyamine production reduces MYC expression, leading to diminished tumor cell viability via the downregulation of cell cycle-related genes. Furthermore, reduced MYC levels are associated with changes in the expression of immunomodulatory cytokines and human leukocyte antigen molecules, pointing to a potential link with enhanced T-cell-mediated cytotoxicity. Collectively, our findings establish a pivotal role for the AZIN1-polyamine axis in osteosarcoma proliferation and immune evasion, and support the development of novel immunotherapeutic strategies targeting polyamine biosynthesis to combat this aggressive cancer.
MEMBER ACCOUNT
登录成功会直接打开下一页。